学习经历

2008.09-2013.06 北京大学/北京生命科学研究所，生物化学与分子生物学 （博士）

2003.09-2008.07 武汉大学医学院，临床医学（学士）；武汉大学生命科学学院，生物科学（学士，双学位）

主要工作经历与任职情况

2022.07-至今　　　  武汉大学泰康生命医学中心，PI

2019.11-至今　　　  武汉大学生命科学学院，病毒学国家重点实验室，PI

2016.08-2019.09　　美国南加州大学医学院分子微生物与免疫学系，博士后

2013.07-2016.08　　北京生命科学研究所/默沙东研发（中国），联合博士后

主要社会兼职

中国研究型医院学会病毒肿瘤学专业委员会常任委员

国际乙肝基金会（HBF）新兴学者科学和医学顾问委员会委员（E-SMAB）

湖北省微生物学会病毒学专业委员会 委员

Nature,Science Advance,Cell report等期刊的审稿人

获奖及荣誉

吴瑞奖学金-吴瑞基金会　2013

湖北省高层次人才项目　2020

主持课题项目

2021-2024年 国自然面上项目 主持

2023-2026年 国自然面上项目 主持

2024-2026年 国自然优秀青年科学基金 主持

2023-2026年 国家重点研发计划 参与（课题骨干）

实验室研究生部分获奖与项目

国家奖学金  3人次

武汉大学“研究生学术创新奖”特等奖  1人次

武汉大学雷军卓越奖学金  1人次

武汉大学十大学术之星 1人次

国家自然科学基金青年学生基础研究项目（博士研究生） 1人次

主要研究领域及兴趣

　　主要从事病毒受体与病毒入侵机制相关研究，致力于寻找、鉴定、设计与优化病毒受体, 建立新型感染模型，揭示受体介导病毒入侵与跨物种传播的分子机制，并开发新型病毒入侵抑制剂，针对人与蝙蝠冠状病毒和乙肝病毒（HBV）等重要疾病相关病毒开展研究并取得了一系列原创性、开创性研究成果，包括（1）成功鉴定HBV受体NTCP，被誉为领域内里程碑式的工作；（2）揭示NeoCoV等蝙蝠MERS相关病毒使用新颖的结合模式识别ACE2为受体，刷新了领域内对MERS簇冠状病毒受体使用的认知；（3）首次提出了“定制化病毒受体”的概念，为多种冠状病毒成功设计了人工受体。

Our research programs focus on virus receptors and the mechanisms of viral entry. We aim to discover, identify, design, and optimize virus receptors, as well as establish infection models based on these receptors. Our interests include understanding how virus surface proteins interact with receptors to promote entry of different viruses, and how this process affects the efficiency of cross-species transmission. We are also dedicated to developing antiviral strategies that target the early stages of viral entry. Professor Huan Yan's major research achievements  include:  

(1) The identification of NTCP as the functional receptor for HBV, which is recognized as a milestone in the field (eLife, 2012)

(2) The identification of ACE2 as receptor for bat MERS-related coronavirus, NeoCoV and PDF-2180 (Nature,2022)

(3) Design of customized coronavirus receptors (Nature,2024)

代表性论文（#并列第一作者，*通讯作者）

研究论文(Articles)：

1. Peng Liu^#, Mei-Ling Huang^#, Hua Guo^#, Matthew McCallum^#, Jun-Yu Si，Yuan-Mei Chen，Chun-Li Wang，Xiao Yu，Lu-Lu Shi，Qing Xiong，Cheng-Bao Ma，John E. Bowen, Fei Tong, Chen Liu, Ye-hui Sun, Xiao Yang，Jing Chen, Ming Guo, Jing Li, Davide Corti, David Veesler^*, Zheng-Li Shi^*, Huan Yan^*. Design of customized coronavirus receptors. Nature. 2024 Oct; doi:10.1038/s41586-024-08121-5（首次提出定制化人工病毒受体）
2. Qing Xiong^#, Lei Cao^#, Chengbao Ma^#, M. Alejandra Tortorici^#, Chen Liu, Junyu Si, Peng Liu, Mengxue Gu, Alexandra C. Walls, Chunli Wang, Lulu Shi, Fei Tong, Meiling Huang, Jing Li, Chufeng Zhao, Chao Shen, Yu Chen, Huabin Zhao, Ke Lan, Davide Corti, David Veesler*, Xiangxi Wang^*, Huan Yan^*. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Nature. 2022 Dec;612(7941):748-757. （首次揭示MERS簇冠状病毒使用ACE2为受体）
3. Junyu Si*, Yuanmei Chen*, Yehui Sun*, Mengxue Gu, Meiling Huang, Lulu Shi, Xiao Yu, Xiao Yang, Qing Xiong, Chenbao Ma, Peng Liu, Zheng-Li Shi, Huan Yan^*. Sarbecovirus RBD indels and specific residues dictating multi-species ACE2 adaptiveness. Nat Commun. 2024 Oct 14;15(1):8869. （揭示SARS相关冠状病毒刺突蛋白RBD的indel等序列特征与多物种受体识别谱的关系）
4. Chengbao Ma^#, Chen Liu^#, Qing Xiong^#, Mengxue Gu, Lulu Shi, Chunli Wang, Junyu Si, Fei Tong, Peng Liu, Meiling Huang, Huan Yan^*. Broad host tropism of ACE2-using MERS-related coronaviruses and determinants restricting viral recognition. Cell Discovery. 2023 Jun 15;9(1):57.（揭示NeoCoV与PDF2180有广泛的受体识别谱）
5. Qianyun Liu^#, Qing Xiong^#, Fanghua Mei^#, Chengbao Ma, Zhen Zhang, Bing Hu, Junqiang Xu, Yongzhong Jiang, Faxian Zhan, Suhua Zhou, Li Tao, Xianying Chen, Ming Guo, Xin Wang, Yaohui Fang, Shu Shen, Yingle Liu, Fang Liu, Li Zhou, Ke Xu, Changwen Ke, Fei Deng, Kun Cai*, Huan Yan^*, Yu Chen^*, Ke Lan^*. Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China. The Innovation. 2022 Jan 25;3(1):100181.
6. Chengbao Ma^#, Xianying Chen^#, Fanghua Mei^#, Qing Xiong, Qianyun Liu, Lianghui Dong, Chen Liu, Wenjing Zou, Faxian Zhan, Bing Hu, Yingle Liu, Fang Liu, Li Zhou, Junqiang Xu, Yongzhong Jiang, Ke Xu, Kun Cai^*, Yu Chen^*, Huan Yan^*，Ke Lan^*. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg Microbes Infect. 2022 Dec;11(1):567-572.
7. Huan Yan^#, Hengwu Jiao^#, Qianyun Liu, Zhen Zhang, Qing Xiong, Bing-Jun Wang, Xin Wang, Ming Guo, Lin-Fa Wang, Ke Lan^*, Yu Chen^* & Huabin Zhao^*. ACE2 receptor usage reveals variation in susceptibility to SARS-CoV and SARS-CoV-2 infection among bat species. Nat Ecol Evol. 2021 May;5(5):600-608.
8. Yang Liu^#, Lei Zhang^#, Huan Yan^#, Zhiqiang Wang, Guoliang Sun, Xiao Song, Zhongmin Zhou, Bo Peng, Liwei Yan, Qingcui Wu, Wenhui Li^*, and Xiangbing Qi* Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors. J. Med. Chem. 2021 May 13;64(9):5973-6007.

9. Huan Yan, Suan-Sin Foo, Weiqiang Chen, Ji-Seung Yoo, Woo-Jin Shin, Christine Wu, Jae U. Jung^*. Efficient inhibition of Human Papillomavirus infection by L2 minor capsid-derived lipopeptide. mBio. 2019 Aug 6;10(4):e01834-19.
10. Huan Yan^#, Bo Peng^#, Yang Liu, Guangwei Xu, Wenhui He, Bijie Ren, Zhiyi Jing, Jianhua Sui, Wenhui Li^*. Viral Entry of Hepatitis B and D Viruses and Bile Salts Transportation Share Common Molecular Determinants on Sodium Taurocholate Cotransporting Polypeptide. J Virol. 2014 Mar;88(6):3273-84.
11. Huan Yan^#, Bo Peng^#, Wenhui He, Guocai Zhong, Yonghe Qi, Bijie Ren, Zhenchao Gao, Zhiyi Jing, Mei Song, Guangwei Xu, Jianhua Sui, Wenhui Li^*.Molecular determinants of hepatitis B and d virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol. 2013 Jul;87(14):7977-91.
12. Shixian Lin^#, Huan Yan^#, Lin Li, Maiyun Yang, Bo Peng, She Chen, Wenhui Li^*, Peng R Chen^*. Site-specific Engineering of Chemical Functionalities on the Surface of Live Hepatitis D Virus. Angew. Chem. Int. Ed. 2013 Dec;52(52), 13970-4.
13. Huan Yan^# , Guocai Zhong^# , Guangwei Xu, Wenhui He, Zhiyi Jing, Zhenchao Gao, Yi Huang, Yonghe Qi, Bo Peng, Haimin Wang, Liran Fu, Mei Song, Pan Chen, Wenqing Gao, Bijie Ren, Yinyan Sun, Tao Cai, Xiaofeng Feng, Jianhua Sui, Wenhui Li^*. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife. 2012; 1: e00049. (Identification of HBV receptor NTCP, a mile stone in the field. （相关研究发现获2020年乙肝研究最高奖Baruch Blumberg奖以及2022年未来科学大奖)

综述(Reviews)：
1. Qing Xiong, Chengbao Ma. Chen Liu, Fei Tong, Meiling Huang, Huan Yan*. ACE2-using merbecoviruses: further evidence of convergent evolution of ACE2 recognition by NeoCoV and other MERS-CoV related viruses. Cell Insight. 2024 Jan 30;3(1):100145. 2.（综述：介绍ACE2在MERS相关冠状病毒中的重要作用）

2. Huan Yan*, Chunli Wang, Key Factors for “Fishing” NTCP as a Functional Receptor for HBV and HDV. Viruses. 2023; 15(2), 512. （综述：HBV受体发现十年后总结当年受体发现的关键细节）

3.Huan Yan, Wenhui Li^*. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Dig Dis. 2015 May; 33(3):388-96.

4. Huan Yan, Yang Liu, Jianhua Sui, Wenhui Li^*. NTCP opens the door for hepatitis B virus infection. Antiviral Res. 2015 Sep;121:24-30.

招生招聘

欢迎对病毒学研究感兴趣的本科生、研究生、博士生或博士后加入我们的团队! 有意向加入者请将简历发送至huanyan@whu.edu.cn。